Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 454

1.

Multicentre evaluation of the new ETEST gradient diffusion method for piperacillin-tazobactam susceptibility testing of Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii complex.

García-Fernandez S, Bala Y, Armstrong T, Garcia-Castillo M, Burnham CA, Wallace MA, Hardy D, Zambardi G, Canton R.

J Clin Microbiol. 2019 Oct 9. pii: JCM.01042-19. doi: 10.1128/JCM.01042-19. [Epub ahead of print]

PMID:
31597745
2.

Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis.

López Y, Tato M, Gargallo-Viola D, Cantón R, Vila J, Zsolt I.

PLoS One. 2019 Oct 9;14(10):e0223326. doi: 10.1371/journal.pone.0223326. eCollection 2019.

3.

Current status of ESKAPE microorganisms in Spain: Epidemiology and resistance phenotypes.

Sánchez-López J, Cantón R.

Rev Esp Quimioter. 2019 Sep;32 Suppl 2:27-31. Review.

4.

Evaluation of rapid colistin susceptibility directly from positive blood cultures using a flow cytometry assay.

Fonseca E Silva D, Silva-Dias A, Gomes R, Martins-Oliveira I, Ramos MH, Rodrigues AG, Cantón R, Pina-Vaz C.

Int J Antimicrob Agents. 2019 Aug 16. pii: S0924-8579(19)30227-4. doi: 10.1016/j.ijantimicag.2019.08.016. [Epub ahead of print]

PMID:
31425793
5.

Mechanisms of action and antimicrobial activity of ceftobiprole.

Morosini MI, Díez-Aguilar M, Cantón R.

Rev Esp Quimioter. 2019 Sep;32 Suppl 3:3-10. Review.

6.

Bronchiectasis: When the Published Scientific Evidence Proves Insufficient.

Martinez-Garcia MA, de la Rosa D, Cantón R, Olveira C, Máiz-Carro L, Girón R, Prados C, Blanco M.

Arch Bronconeumol. 2019 Jun;55(6):283-285. doi: 10.1016/j.arbres.2019.05.001. English, Spanish. No abstract available.

7.

Hypermucoviscous Klebsiella pneumoniae: A challenge in community acquired infection.

Sánchez-López J, García-Caballero A, Navarro-San Francisco C, Quereda C, Ruiz-Garbajosa P, Navas E, Dronda F, Morosini MI, Cantón R, Diez-Aguilar M.

IDCases. 2019 May 3;17:e00547. doi: 10.1016/j.idcr.2019.e00547. eCollection 2019.

8.

Outbreak of NDM-1+CTX-M-15+DHA-1-producing Klebsiella pneumoniae high-risk clone in Spain owing to an undetectable colonised patient from Pakistan.

Hernández-García M, Pérez-Viso B, León-Sampedro R, Navarro-San Francisco C, López-Fresneña N, Díaz-Agero C, Morosini MI, Ruiz-Garbajosa P, Cantón R.

Int J Antimicrob Agents. 2019 Aug;54(2):233-239. doi: 10.1016/j.ijantimicag.2019.05.021. Epub 2019 Jun 4.

PMID:
31173865
9.

Eikenella corrodens causing deep-seated infections. Six-year experience in a University Hospital in Madrid.

Rodríguez-Rojas L, Suarez-López A, Cantón R, Ruiz-Garbajosa P.

Enferm Infecc Microbiol Clin. 2019 May 28. pii: S0213-005X(19)30164-8. doi: 10.1016/j.eimc.2019.04.004. [Epub ahead of print] English, Spanish.

PMID:
31151817
10.

Microbiological profile of ozenoxacin.

Morrissey I, Cantón R, Vila J, Gargallo-Viola D, Zsolt I, Garcia-Castillo M, López Y.

Future Microbiol. 2019 Jun;14:773-787. doi: 10.2217/fmb-2019-0089. Epub 2019 May 28.

11.

New microbiological aspects of fosfomycin.

Díez-Aguilar M, Cantón R.

Rev Esp Quimioter. 2019 May;32 Suppl 1:8-18. Review.

12.

Whole-genome sequencing reveals nosocomial Clostridioides difficile transmission and a previously unsuspected epidemic scenario.

García-Fernández S, Frentrup M, Steglich M, Gonzaga A, Cobo M, López-Fresneña N, Cobo J, Morosini MI, Cantón R, Del Campo R, Nübel U.

Sci Rep. 2019 May 6;9(1):6959. doi: 10.1038/s41598-019-43464-4.

13.

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.

Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P; Antimicrobial Resistance International Working Group in Cystic Fibrosis.

Clin Infect Dis. 2019 May 6. pii: ciz364. doi: 10.1093/cid/ciz364. [Epub ahead of print]

PMID:
31056660
14.

Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies.

Gudiol C, Aguilar-Guisado M, Azanza JR, Candel FJ, Cantón R, Carratalà J, Garcia-Vidal C, Jarque I, Lizasoain M, Gil-Bermejo JM, Ruiz-Camps I, Sánchez-Ortega I, Solano C, Suárez-Lledó M, Vázquez L, de la Cámara R.

Enferm Infecc Microbiol Clin. 2019 Mar 26. pii: S0213-005X(19)30130-2. doi: 10.1016/j.eimc.2019.01.013. [Epub ahead of print] English, Spanish.

PMID:
30926172
15.

Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program.

Castanheira M, Deshpande LM, Mendes RE, Canton R, Sader HS, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S23-S33. doi: 10.1093/ofid/ofy347. eCollection 2019 Mar.

16.

Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems.

Cantón R, Oliver A, Alós JI, de Benito N, Bou G, Campos J, Calvo J, Canut A, Castillo J, Cercenado E, Domínguez MÁ, Fernández-Cuenca F, Guinea J, Larrosa N, Liñares J, López-Cerero L, López-Navas A, Marco F, Mirelis B, Moreno-Romo MÁ, Morosini MI, Navarro F, Oteo J, Pascual Á, Pérez-Trallero E, Pérez-Vázquez M, Soriano A, Torres C, Vila J, Martínez-Martínez L.

Enferm Infecc Microbiol Clin. 2019 Mar 13. pii: S0213-005X(19)30135-1. doi: 10.1016/j.eimc.2019.01.017. [Epub ahead of print] Review. English, Spanish.

PMID:
30878313
17.

Local prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in Klebsiella pneumoniae: a prevalence survey in a Spanish University Hospital.

Díaz-Agero Pérez C, López-Fresneña N, Rincon Carlavilla AL, Hernandez Garcia M, Ruiz-Garbajosa P, Aranaz-Andrés JM, Maechler F, Gastmeier P, Bonten MJM, Canton R.

BMJ Open. 2019 Mar 1;9(3):e024879. doi: 10.1136/bmjopen-2018-024879.

18.

Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.

García-Fernández S, García-Castillo M, Bou G, Calvo J, Cercenado E, Delgado M, Pitart C, Mulet X, Tormo N, Mendoza DL, Díaz-Regañón J, Cantón R; SUPERIOR Study Group.

Int J Antimicrob Agents. 2019 May;53(5):682-688. doi: 10.1016/j.ijantimicag.2019.02.004. Epub 2019 Feb 12.

PMID:
30769199
19.

Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).

Cantón R, Loza E, Aznar J, Castillo FJ, Cercenado E, Fraile-Ribot PA, González-Romo F, López-Hontangas JL, Rodríguez-Lozano J, Suárez-Barrenechea AI, Tubau F, Díaz-Regañón J, López-Mendoza D; SMART-Spain Working Group.

Rev Esp Quimioter. 2019 Apr;32(2):145-155. Epub 2019 Feb 13.

20.

Direct antimicrobial susceptibility testing from the blood culture pellet obtained for MALDI-TOF identification of Enterobacterales and Pseudomonas aeruginosa.

López-Pintor JM, Navarro-San Francisco C, Sánchez-López J, García-Caballero A, Loza Fernández de Bobadilla E, Morosini MI, Cantón R.

Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1095-1104. doi: 10.1007/s10096-019-03498-y. Epub 2019 Feb 2.

PMID:
30712228
21.

Simulating Multilevel Dynamics of Antimicrobial Resistance in a Membrane Computing Model.

Campos M, Capilla R, Naya F, Futami R, Coque T, Moya A, Fernandez-Lanza V, Cantón R, Sempere JM, Llorens C, Baquero F.

MBio. 2019 Jan 29;10(1). pii: e02460-18. doi: 10.1128/mBio.02460-18.

22.

Ozenoxacin: a review of preclinical and clinical efficacy.

Vila J, Hebert AA, Torrelo A, López Y, Tato M, García-Castillo M, Cantón R.

Expert Rev Anti Infect Ther. 2019 Mar;17(3):159-168. doi: 10.1080/14787210.2019.1573671. Epub 2019 Feb 11. Review.

PMID:
30686133
23.

Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Abodakpi H, Chang KT, Gao S, Sánchez-Díaz AM, Cantón R, Tam VH.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01906-18. doi: 10.1128/AAC.01906-18. Print 2019 Feb.

24.

From CLSI to EUCAST, a necessary step in Spanish laboratories.

Larrosa MN, Benito N, Cantón R, Canut A, Cercenado E, Fernández-Cuenca F, Guinea J, López-Navas A, Moreno MÁ, Oliver A, Martínez-Martínez L.

Enferm Infecc Microbiol Clin. 2018 Nov 5. pii: S0213-005X(18)30278-7. doi: 10.1016/j.eimc.2018.09.014. [Epub ahead of print] Review. English, Spanish.

PMID:
30409509
25.

Current approach to fosfomycin: From bench to bedside.

Candel FJ, Cantón R.

Enferm Infecc Microbiol Clin. 2019 Jan;37(1):1-3. doi: 10.1016/j.eimc.2018.10.002. Epub 2018 Oct 22. English, Spanish. No abstract available.

PMID:
30360920
26.

Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study "MFIP".

Delhaes L, Touati K, Faure-Cognet O, Cornet M, Botterel F, Dannaoui E, Morio F, Le Pape P, Grenouillet F, Favennec L, Le Gal S, Nevez G, Duhamel A, Borman A, Saegeman V, Lagrou K, Gomez E, Carro ML, Canton R, Campana S, Buzina W, Chen S, Meyer W, Roilides E, Simitsopoulou M, Manso E, Cariani L, Biffi A, Fiscarelli E, Ricciotti G, Pihet M, Bouchara JP.

J Cyst Fibros. 2019 Mar;18(2):212-220. doi: 10.1016/j.jcf.2018.10.001. Epub 2018 Oct 20. No abstract available.

PMID:
30348610
27.

Early prosthetic endocarditis caused by Stenotrophomonas maltophilia.

Morte E, Tolmos M, Halperin A, Morosini MI, Cantón R, Hermida JM.

Med Mal Infect. 2018 Dec;48(8):543-546. doi: 10.1016/j.medmal.2018.09.004. Epub 2018 Oct 15. Review. No abstract available.

PMID:
30336969
28.

Defining antimicrobial resistance in cystic fibrosis.

Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ; Antimicrobial Resistance in Cystic Fibrosis International Working Group.

J Cyst Fibros. 2018 Nov;17(6):696-704. doi: 10.1016/j.jcf.2018.08.014. Epub 2018 Sep 25. Review.

PMID:
30266518
29.

Emergence and dissemination of colistin-resistant Klebsiella pneumoniae isolates expressing OXA-48 plus CTX-M-15 in patients not previously treated with colistin in a Spanish university hospital.

Barragán-Prada H, Ruiz-Hueso P, Tedim AP, González-Candelas F, Galán JC, Cantón R, Morosini MI.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):147-153. doi: 10.1016/j.diagmicrobio.2018.08.014. Epub 2018 Sep 8.

PMID:
30266401
30.

Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients.

Díez-Aguilar M, Ekkelenkamp M, Morosini MI, Merino I, de Dios Caballero J, Jones M, van Westreenen M, Tunney MM, Cantón R, Fluit AC.

Int J Antimicrob Agents. 2019 Jan;53(1):84-88. doi: 10.1016/j.ijantimicag.2018.09.001. Epub 2018 Sep 19.

PMID:
30240837
31.

Changes in bacterial hospital epidemiology.

Morosini MI, Cantón R.

Rev Esp Quimioter. 2018 Sep;31 Suppl 1:23-26. Review.

32.

First Report of an OXA-48- and CTX-M-213-Producing Kluyvera Species Clone Recovered from Patients Admitted in a University Hospital in Madrid, Spain.

Hernández-García M, León-Sampedro R, Pérez-Viso B, Morosini MI, López-Fresneña N, Díaz-Agero C, Coque TM, Ruiz-Garbajosa P, Cantón R.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01238-18. doi: 10.1128/AAC.01238-18. Print 2018 Nov.

33.

MIC-based dose adjustment: facts and fables-authors' response.

Mouton JW, Muller AE, Canton R, G Giske C, Kahlmeter G, Turnidge J.

J Antimicrob Chemother. 2018 Sep 1;73(9):2585-2586. doi: 10.1093/jac/dky195. No abstract available.

PMID:
30137389
34.

Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe.

Merino I, Hernández-García M, Turrientes MC, Pérez-Viso B, López-Fresneña N, Diaz-Agero C, Maechler F, Fankhauser-Rodriguez C, Kola A, Schrenzel J, Harbarth S, Bonten M, Gastmeier P, Canton R, Ruiz-Garbajosa P; R-GNOSIS Study Group.

J Antimicrob Chemother. 2018 Nov 1;73(11):2973-2980. doi: 10.1093/jac/dky296.

PMID:
30124851
35.

Performance of CHROMID® Colistin R agar, a new chromogenic medium for screening of colistin-resistant Enterobacterales.

García-Fernández S, García-Castillo M, Ruiz-Garbajosa P, Morosini MI, Bala Y, Zambardi G, Cantón R.

Diagn Microbiol Infect Dis. 2019 Jan;93(1):1-4. doi: 10.1016/j.diagmicrobio.2018.07.008. Epub 2018 Aug 7.

PMID:
30097296
36.

Characterization of carbapenemase-producing Enterobacteriaceae from colonized patients in a university hospital in Madrid, Spain, during the R-GNOSIS project depicts increased clonal diversity over time with maintenance of high-risk clones.

Hernández-García M, Pérez-Viso B, Carmen Turrientes M, Díaz-Agero C, López-Fresneña N, Bonten M, Malhotra-Kumar S, Ruiz-Garbajosa P, Cantón R.

J Antimicrob Chemother. 2018 Nov 1;73(11):3039-3043. doi: 10.1093/jac/dky284.

PMID:
30053018
37.

Multicenter Evaluation of the Xpert Carba-R Assay for Detection of Carbapenemase Genes in Gram-Negative Isolates.

Traczewski MM, Carretto E, Canton R, Moore NM; Carba-R Study Team.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00272-18. doi: 10.1128/JCM.00272-18. Print 2018 Aug.

38.

Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.

Canton R, Morrissey I, Vila J, Tato M, García-Castillo M, López Y, Gargallo-Viola D, Zsolt I.

Future Microbiol. 2018 May 1;13:3-19. doi: 10.2217/fmb-2017-0289.

39.

A review of the antibacterial activity of ozenoxacin.

Canton R, Chouinard L, Tarragó C.

Future Microbiol. 2018 May 1;13:1-2. doi: 10.2217/fmb-2018-0069. No abstract available.

40.

Ceftazidime Is the Key Diversification and Selection Driver of VIM-Type Carbapenemases.

Martínez-García L, González-Alba JM, Baquero F, Cantón R, Galán JC.

MBio. 2018 May 8;9(3). pii: e02109-17. doi: 10.1128/mBio.02109-17.

41.

Antimicrobial susceptibility trends and evolution of isolates with extended spectrum β-lactamases among Gram-negative organisms recovered during the SMART study in Spain (2011-2015).

Cantón R, Loza E, Aznar J, Barrón-Adúriz R, Calvo J, Castillo FJ, Cercenado E, Cisterna R, González-Romo F, López-Hontangas JL, Suárez-Barrenechea AI, Tubau F, Molloy B, López-Mendoza D; SMART-Spain Working Group.

Rev Esp Quimioter. 2018 Apr;31(2):136-145. Epub 2018 Mar 12.

42.

Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Mensa J, Barberán J, Soriano A, Llinares P, Marco F, Cantón R, Bou G, González Del Castillo J, Maseda E, Azanza JR, Pasquau J, García-Vidal C, Reguera JM, Sousa D, Gómez J, Montejo M, Borges M, Torres A, Alvarez-Lerma F, Salavert M, Zaragoza R, Oliver A.

Rev Esp Quimioter. 2018 Feb;31(1):78-100. Epub 2018 Feb 23. Review.

43.

Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.

García-Castillo M, García-Fernández S, Gómez-Gil R, Pitart C, Oviaño M, Gracia-Ahufinger I, Díaz-Regañón J, Tato M, Cantón R; iCREST Study Group.

Int J Antimicrob Agents. 2018 Mar;51(3):511-515. doi: 10.1016/j.ijantimicag.2018.01.011. Epub 2018 Jan 31.

PMID:
29371104
44.

The what, when and how in performing and interpreting microbiological diagnostic tests in skin and soft tissue infections.

Navarro-San Francisco C, Ruiz-Garbajosa P, Cantón R.

Curr Opin Infect Dis. 2018 Apr;31(2):104-112. doi: 10.1097/QCO.0000000000000433. Review.

PMID:
29337704
45.

Potential Impact of Flow Cytometry Antimicrobial Susceptibility Testing on the Clinical Management of Gram-Negative Bacteremia Using the FASTinov® Kit.

Costa-de-Oliveira S, Teixeira-Santos R, Silva AP, Pinho E, Mergulhão P, Silva-Dias A, Marques N, Martins-Oliveira I, Rodrigues AG, Paiva JA, Cantón R, Pina-Vaz C.

Front Microbiol. 2017 Dec 12;8:2455. doi: 10.3389/fmicb.2017.02455. eCollection 2017.

46.

Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Bordallo-Cardona MÁ, Marcos-Zambrano LJ, Sánchez-Carrillo C, de la Pedrosa EGG, Cantón R, Bouza E, Escribano P, Guinea J.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01982-17. doi: 10.1128/AAC.01982-17. Print 2018 Mar.

47.

Fungi in Bronchiectasis: A Concise Review.

Máiz L, Nieto R, Cantón R, Gómez G de la Pedrosa E, Martinez-García MÁ.

Int J Mol Sci. 2018 Jan 4;19(1). pii: E142. doi: 10.3390/ijms19010142. Review.

48.

Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance.

De Waele JJ, Akova M, Antonelli M, Canton R, Carlet J, De Backer D, Dimopoulos G, Garnacho-Montero J, Kesecioglu J, Lipman J, Mer M, Paiva JA, Poljak M, Roberts JA, Rodriguez Bano J, Timsit JF, Zahar JR, Bassetti M.

Intensive Care Med. 2018 Feb;44(2):189-196. doi: 10.1007/s00134-017-5036-1. Epub 2017 Dec 29.

PMID:
29288367
49.

Susceptibility testing and detection of β-lactam resistance mechanisms in Enterobacteriaceae: a multicentre national proficiency study.

Díez-Aguilar M, Conejo MC, Morosini MI, Tormo Palop N, Gimeno C, Cantón R, Pascual Á.

Int J Antimicrob Agents. 2018 Apr;51(4):612-619. doi: 10.1016/j.ijantimicag.2017.12.008. Epub 2017 Dec 21.

PMID:
29274802
50.

Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of Candida glabrata.

Bordallo-Cardona MÁ, Escribano P, Marcos-Zambrano LJ, Díaz-García J, de la Pedrosa EG, Cantón R, Bouza E, Guinea J.

Med Mycol. 2018 Oct 1;56(7):903-906. doi: 10.1093/mmy/myx124.

PMID:
29228268

Supplemental Content

Loading ...
Support Center